Patients with diabetes mellitus (DM) often present other chronic comorbidities including arterial hypertension (AH), chronic kidney disease (CKD), ischemic heart disease (IHD) and heart failure with preserved ejection fraction (HFpEF). The frequent association of the latter conditions is considered part of the spectrum of cardio-renal syndromes (CRS), a group of disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other. Verapamil is a non-dihydropyridine calcium channel blocker (CCB) widely used in the treatment of hypertension, chronic stable angina, secondary prevention of reinfarction, paroxysmal supra-ventricular tachycardia and for rate control in atrial fibrillation/flutter. In addition to its antihypertensive and anti-ischemic actions verapamil exerts favorable effects also on glycemic control, proteinuric diabetic nephropathy, left ventricular diastolic dysfunction and sympathetic nervous system overactivity which may potentially benefit patients with DM and CRS. In this narrative review, we summarize the current evidence on the potential role of verapamil in the prevention and treatment of CRS in diabetic hypertensive patients.

Lido, P., Romanello, D., Tesauro, M., Bei, A., Perrone, M.a., Palazzetti, D., et al. (2022). Verapamil: Prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients?. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 26(5), 1524-1534 [10.26355/eurrev_202203_28217].

Verapamil: Prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients?

Romanello D.;Tesauro M.;Perrone M. A.;Noce A.;
2022-01-01

Abstract

Patients with diabetes mellitus (DM) often present other chronic comorbidities including arterial hypertension (AH), chronic kidney disease (CKD), ischemic heart disease (IHD) and heart failure with preserved ejection fraction (HFpEF). The frequent association of the latter conditions is considered part of the spectrum of cardio-renal syndromes (CRS), a group of disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other. Verapamil is a non-dihydropyridine calcium channel blocker (CCB) widely used in the treatment of hypertension, chronic stable angina, secondary prevention of reinfarction, paroxysmal supra-ventricular tachycardia and for rate control in atrial fibrillation/flutter. In addition to its antihypertensive and anti-ischemic actions verapamil exerts favorable effects also on glycemic control, proteinuric diabetic nephropathy, left ventricular diastolic dysfunction and sympathetic nervous system overactivity which may potentially benefit patients with DM and CRS. In this narrative review, we summarize the current evidence on the potential role of verapamil in the prevention and treatment of CRS in diabetic hypertensive patients.
2022
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/11
English
Cardio-renal syndromes
Diabetes mellitus
Diabetic nephropathy
Heart failure with preserved ejection fraction
Hypertension
Ischemic heart disease
Proteinuria
Verapamil
Lido, P., Romanello, D., Tesauro, M., Bei, A., Perrone, M.a., Palazzetti, D., et al. (2022). Verapamil: Prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients?. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 26(5), 1524-1534 [10.26355/eurrev_202203_28217].
Lido, P; Romanello, D; Tesauro, M; Bei, A; Perrone, Ma; Palazzetti, D; Noce, A; Di Lullo, L; Calo, L; Cice, G
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/352717
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact